The Gadolinium-based Contrast Media Market was $456.32 Mn in 2020, and it is highly expected to reach $678.40 Mn by 2030. It is eventually growing at a commendable high compound of annual growth rate CAGR of 4.0% between 2020-2030. But due to the current COVID-19 pandemic, there might be a slight difference in the growth rate in the present year. Increased prevalence of the different advancements in technologies and the long-term chronic diseases will help to accelerate the growth of this market. The major factor that drives the growth of this market is the growing prevalence of complex morbidities and label expansion like acquisitions and mergers by the key players. These factors will help to accelerate the growth of this market during the forecasted period.
Gadolinium-based Contrast Media Market Is Estimated To Witness Remarkable Growth
Source: SAI Research
The Gadolinium-based Contrast Media Market has been segmented into type, modality, and indication. By Type – Extracellular Agents, Blood Pool Agents, Hepatobiliary Agents. By Modality – MRI, MRA. By Indication – Cardiovascular, Neurology, Cancer, Others (Musculoskeletal). The cardiovascular segment is expected to register fast growth in the market during the forecasted period. It is because Cardiovascular MRI is being employed to evaluate the complex congenital heart diseas, morphology study of vascular structure, ischemic heart disease, and cardiac disease.
Major Players In Gadolinium-based Contrast Media Market
Some of the major players in the Gadolinium-based Contrast Media Market include Bayer AG, GE Healthcare, Guerbet, Lantheus Medical Imaging, Inc., Bracco Diagnostic, Inc., and Trivitron Healthcare.
The Gadolinium-based Contrast Media Market Has Been Segmented Into:
Gadolinium-based Contrast Media Market, By Type
Gadolinium-based Contrast Media Market, By Modality
Gadolinium-based Contrast Media Market, By Indication
Gadolinium-based Contrast Media Market, By Region
Customization options available to meet your custom research requirements :